15 September 2026 in SSRN Electronic Journal
MSMarta Szulc-Gasiorowska
Trinucleotide-based capping reagents (m7GpppN1pN2 derivatives) have significantly expanded the number of chemical modifications that can be incorporated into the mRNA 5’ end during co-transcriptional capping, particularly within the first transcribed nucleotide (N1). So far, cap1-based structures comprising adenosine at the N1 position have been mostly explored. Herein, we investigate the modifications of cap1 structures incorporating guanosine at N1. We developed a straightforward synthetic route based on one-pot N-alkylation of guanosine phosphoramidites, followed by solid-phase synthesis, to prepare a series of trinucleotide cap analogs modified at the N1- and N2-positions of guanosine with methyl and benzyl groups. Biochemical evaluation revealed that while the T7 RNA polymerase active site is highly sensitive to modifications at the N1 site, the N2-substituted compounds are remarkably well-tolerated during in vitro transcription. All compounds were properly recognized by the translational initiation factor eIF4E and, after incorporation into short RNA, showed varied susceptibilities to the recombinant decapping enzyme, hDcp2. Translation assays for reporter mRNAs in A549 and JAWS II cells revealed that the novel modifications are generally compatible with translational machinery. While none of the mRNAs with modified guanosine caps reached the high expression levels of the m7GpppAmpG-capped reference, select analogs outperformed the unmodified m7GpppGmpG –most notably the N2-methyl variant (m7Gpppm2GmpG), which yielded up to a 1.7-fold increase in expression. The N2-methyl analog emerged as the most promising compound among the synthesized series, combining robust capping efficiency, high eIF4E affinity, and intermediate susceptibility to hDcp2-mediated decapping in vitro. Overall, these results demonstrate that N-modified guanosine caps may serve as valuable chemical tools for tuning cap-protein interactions and enzymatic susceptibility in next-generation mRNA design.